^
Association details:
| Biomarker: | IDH2 mutation + SRSF2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
Published date:
04/22/2021
Excerpt:
...patients treated with HMA+VEN-based regimens at The University of Texas MD Anderson Cancer Center...IDH2 mutations were enriched in patients with SRSF2 mutations and associated with favorable outcomes (1- and 2-year overall survival [OS] of 100% and 88%).
Secondary therapy:
Hypomethylating agent
DOI:
10.1182/bloodadvances.2020004173
